11. Myasthenia gravis Clinical trials / Disease details

Clinical trials : 315 /  Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02102594
(ClinicalTrials.gov)		October 201425/3/2014Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)Myasthenia Gravis;Systemic Lupus Erythematosus;Rheumatoid ArthritisDrug: BortezomibCharite University, Berlin, GermanyProf. Dr. med. Falk Hiepe (Charité, Internal Medicine / Rheumathology);NeuroCure Clinical Research Center, Charite, BerlinTerminated18 Years75 YearsAll11Phase 2Germany
2EUCTR2013-005362-19-DE
(EUCTR)		17/07/201418/12/2013Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB)Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB) - TAVAB Myasthenia Gravis Systemic Lupus ErythematosusRheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Velcade®
INN or Proposed INN: BORTEZOMIB		Charité - Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes		18Phase 2Germany